ondansetron.txt

CLINICAL USE

Anti-emetic

DOSE IN NORMAL RENAL FUNCTION

Oral: 4–24 mg daily in 2–3 divided dosesIV: 8–32 mg dailyPR: 16 mg pre-chemotherapy

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :293.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :70–76

%Excreted unchanged in urine &nbsp &nbsp : <5

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :2

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3–6/5.4

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral, IV, IM, rectal

Rate of Administration

IV bolus over 3–5 minutes

IV infusion

: over 15 minutes Continuous infusion: 1 mg/hour

Comments

Dilute in 50–100 mL of sodium chloride 0.9% or glucose 5%

OTHER INFORMATION

Can be used to treat uraemic pruritus Renal clearance of ondansetron is low

Tags: post-by-auto-php